Positive results for first Phase III study of long-acting, injectable HIV-treatment regimen

ViiV Healthcare (Brentford, UK) have announced positive 48-week results from the Phase III ATLAS study, which examined a long-acting, injectable, two-drug regimen for treating HIV.

The study, which was open-label, recruited 618 men and women at research centers across 13 different countries. The trial was designed to assess if HIV-1 infected patients, who had maintained viral suppression for > 6 months on a three-drug oral regimen, could maintain the same levels of viral suppression upon switching to the investigational, long-acting, two-drug injectable regimen.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment